

Transgene files 2 patents on therapeutic AIDS vaccine and Multiple Sclerosis drug

March 22, 2010

Transgene is happy to announce that they have filed 2 new patents for their proprietary and novel autoimmune technology platform.

The first patent, for a therapeutic AIDS vaccine, was filed after it crossed a significant milestone in proving its effectiveness by selectively killing more than 75% of the gp120 specific B cells within 48 hours of administration. This vaccine works by restoring the body's natural cellular immune responses against HIV, leading to the containment of the HIV infection, and almost reversing the process of AIDS. Another significant feature of this drug is its safety for the rest of the immune system. To date, more than 25 million lives have been claimed by AIDS and 33 million people are estimated to have HIV.

The second patent, for a drug against the serious neurological disorder Multiple Sclerosis, also employs Transgene's proprietary autoimmune technology platform. Multiple Sclerosis is the most common progressive and disabling neurological condition in young adults. Approximately 2.5 million people worldwide have Multiple Sclerosis.

The AIDS vaccine and the Multiple Sclerosis drug are the first products to come out of Transgene's autoimmune technology platform, and the 2 patents filed by Transgene serve to reaffirm and protect the novelty in the technology platform. The platform can also be extended against other autoimmune diseases such as Rheumatoid Arthritis and Crohn's Disease etc.

Transgene also filed 2 patents earlier this year for cancer drugs built on Transgene's proprietary RNAi platform, which have been validated by the results of animal studies, and utilize a novel gene silencing technology to selectively knock-down specific cancer-producing gene targets.